Royalty Report: Drugs, Cancer, Disease – Collection: 29382


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29382

License Grant
Ixabepilone was developed by the Company, but is subject to a License Agreement with a German Licensor, relating to epothilone technologies.
License Property
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog[1] developed as a cancer drug.  Ixempra(ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs.

The Company manufactures its bulk requirements for ixabepilone in its own facilities including the manufacturing of the active ingredient. The drug product which comprises a pharmaceutical kit is finished by Baxter Oncology GmbH.

Field of Use
In October 2007, the FDA approved ixabepilone in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated, and in monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.

IPSCIO Record ID: 299281

License Grant
University grants a worldwide, exclusive license under the Patent Rights to make and have made, to use and have used, and to offer to sell, sell or import, and have offered to sell, sold or imported, the Licensed Products in the Field of Use, and to practice and have practiced the Licensed Processes and Know-How.

University also grants the right to enter into sublicensing agreements under the Patent Rights.

License Property
The University rights are for the Method for Synthesizing Epothilones and Epothilone Analogs and any other U.S. application owned by the University that has Valid Claims covering the manufacture, use, or sale of [trans-9,10-dehydro-epothilon,D].

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.

KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.

Field of Use
The Licensee is developing its epothilone, KOS-1584, in Phase 1 clinical trials and it has shown activity in patients with non-small cell lung, ovarian, breast, pancreatic, prostate and other cancers.

IPSCIO Record ID: 238988

License Grant
Licensor grants a sole and exclusive license to the Swiss Licensee, with a right to sublicense, under the Licensor Patent Rights and Licensor Know-How to develop, use, sell, offer for sale, import and/or export Compounds and Licensed Products in the Territory and in the Field, and make and have made Compounds and Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.
License Property
Licensor owns or possesses certain patent rights, know-how and regulatory filings with respect to epothilones, including epothilone D, and believes that epothilone D has the potential to become an anti-cancer agent.

Compound means any epothilone, or analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, a compound that is analog, derivative, prodrug or metabolite of an epothilone, including but not limited to epothilone A, B, C and D, and any compound identified in scientific journals or patent publications as an epothilon, analog, derivative, prodrug or metabolite.

Back-Up Compound means a Compound other than epothilone D that may be suitable for development for use in the Field, until and unless it comes to be included in a Replacement Licensed Product.

Licensed Product means any product containing a Compound, the Commercialization of which would either use Licensor Know-How, including without limitation because the product was researched or developed using Licensor Know-How or but for this Agreement, infringe a Valid Claim.

Field of Use
Field means the treatment, palliation, and/or prevention of cancer.  Potential applications include breast cancer and non-hodgkin lymphoma.

IPSCIO Record ID: 259856

License Grant
Licensor grants an exclusive sublicense even as to Licensor under the Sublicensed Subject Matter to research, develop, manufacture, have manufactured, use, import, offer to sell and/or sell Sublicensed Products within the Sublicensed Territory for use within the Sublicensed Field.
License Property
The grant is for certain intellectual property rights, including rights to Annamycin, Licensors WP1122 portfolio, and WP1066 portfolio in the field of non-human animals.

Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.

Field of Use
The Sublicensed Field means the use of Licensed Product for the treatment of cancer in non-human animals through any type of administration.

Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.

IPSCIO Record ID: 28789

License Grant
The Licensor entered into a License Agreement with the Licensee in relation to EVO 022, EVO 033 and EVO 044. EVO 022 is a combination drug therapy which is focused on the treatment of breast cancer. EVO 033 is a reformulation of an off patent novel anti microtubule agent targeted against breast cancer. EVO 044 utilises a stem cell technology to form bone marrow.
License Property
The Licensor acquires, develops and commercializes drugs to treat a variety of cancers, including pancreatic, renal and small-cell lung cancer.
Field of Use
The Licensee is a Pharmaceutical Company.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.